Prevalence of SARS-CoV-2 Antibodies in Children and Adults with Type 1 Diabetes

Jia, Xiaofan; Gesualdo, Patricia; Rasmussen, Cristy Geno; Alkanani, Aimon A.; He, Lin; Dong, Fran; Rewers, Marian; Michels, Aaron; Yu, Liping

doi:10.1089/dia.2020.0609

Cited by 29 publications

(19 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study also showed regional differences in the prevalence of antibodies: it is highest in the Brussels region (24%). As in another study [9], our results in the specific population of children with newly diagnosed type 1 diabetes are quite similar to that of the general population.…”

supporting

confidence: 89%

Anti-SARS-CoV-2 antibodies in new-onset type 1 diabetes in children during pandemic in Belgium

Messaaoui

Hajselova

Tenoutasse

2021

Journal of Pediatric Endocrinology and Metabolism

View full text Add to dashboard Cite

Objectives Questions are emerging concerning the long-term consequences of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, as a possible increase in type 1 diabetes. This study aims to describe the prevalence of anti-SARS-CoV-2 antibodies in children developing type 1 diabetes during this pandemic in Belgium. Methods This observational study included children and adolescents (under 16 years) admitted with new-onset type 1 diabetes. SARS-CoV-2 serology was taken within the first month of diabetes. Results Of the 75 participants, anti-SARS-CoV-2 antibodies were positive in 20% of patients. They had an increased bicarbonate and base excess at diagnosis. Overall 29% of patients presented diabetic ketoacidosis at diagnosis and 9% of them were positive for anti-SARS-CoV-2 antibodies. Insulinoma-associated protein 2 antibodies positivity had significantly higher frequencies in children without anti-SARS-CoV-2 antibodies (49 (81%) vs. 5 (33%), p=0.038). Nine (15%) patients, initially seronegative, have developed anti-SARS-CoV-2 antibodies between the two samples (mean time 8 ± 4 weeks). Conclusions The prevalence of anti-SARS-CoV-2 antibodies in children with newly diagnosed type 1 diabetes (20%) is similar to that found in children without diabetes in Belgium, a country severely affected by this pandemic.

show abstract

supporting

confidence: 89%

Anti-SARS-CoV-2 antibodies in new-onset type 1 diabetes in children during pandemic in Belgium

Messaaoui

Hajselova

Tenoutasse

2021

Journal of Pediatric Endocrinology and Metabolism

View full text Add to dashboard Cite

show abstract

“…As reported in the literature, an interaction between COVID-19 and glucose-insulin metabolic disorders is postulated in adults [1,29] and not excluded in pediatrics [30,31]. In particular, the relationship between COVID-19 and type 2 diabetes mellitus (T2DM) has been extensively described in adults [1,2,30] and a relationship between SARS-CoV-2 infection and type 1 diabetes mellitus (T1DM) has also been discussed in children [30][31][32][33][34][35][36].…”

Section: Discussionmentioning

confidence: 99%

Impaired Glucose-Insulin Metabolism in Multisystem Inflammatory Syndrome Related to SARS-CoV-2 in Children

et al. 2021

View full text Add to dashboard Cite

An interaction between metabolic glucose impairment and coronavirus disease 2019 is reported. The development of a severe multisystem inflammatory syndrome in children (MIS-C) related to SARS-CoV-2 infection has been described. We evaluated the impact of MIS-C on glycemic patterns in pediatric patients. A group of 30 children and adolescents affected by MIS-C were considered; all patients were normal weight. Clinical and biochemical assessments, including surrogate markers of insulin resistance (IR) such as homeostasis model analysis-IR (HOMA-IR) and triglyceride–glucose (TyG) indexes, were recorded. Patients were also invited to undergo an intermittently scanned continuous glucose monitoring (isCGM). HOMA-IR index was calculated in 18 patients (60%), of which 17 (94%) revealed a pathological value. TyG index was computed for all patients and pathological values were detected in all cases. In 15 patients, isCGM data were recorded on average for 9 days (±3 days). Overall, average glucose was 105 mg/dL (±16 mg/dL) and average time spent in the 70–180 mg/dL range (TIR) was 93.76%, with nearly 10% of glucose readings in the 141–180 mg/dL range; glycemic fluctuations over the hyperglycemic threshold were detected in four patients. Regular glucose monitoring may be useful to prevent metabolic imbalance and obtain a better outcome.

show abstract

“…Much attention has been paid to the different comorbidities involving individuals infected by SARS-CoV-2 [ 2 , 3 ]. Diabetes is not associated with a higher risk to contract the infection [ 4 , 5 ], but worsens the prognosis of infected people [ 6 ] leading frequently to hospital admission, acute respiratory syndrome and mortality [ 7 , 8 ]. A recent English whole-population analysis showed that both type 1 and type 2 diabetes were independently associated with a more than two-fold increased risk of in-hospital death with COVID-19 [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Glucose control in home-isolated adults with type 1 diabetes affected by COVID-19 using continuous glucose monitoring

Longo

Scappaticcio

Petrizzo

et al. 2021

J Endocrinol Invest

View full text Add to dashboard Cite

Purpose This study is aimed at evaluating changes in metrics of glucose control in home-isolated patients with type 1 diabetes and COVID-19 using a continuous glucose monitoring (CGM) system. Methods We included adults aged 18–45 years with type 1 diabetes, using CGM, followed by telemedicine at a Southern Italian University Hospital. Thirty-two home-quarantined subjects with SARS-CoV-2 positive swab constituted the COVID-19 group. Thirty age-matched diabetic individuals without COVID-19 formed the control group. The effects of COVID-19 on glycemic control in patients infected were assessed at different time points [2 weeks before-COVID-19 (Time 1), 2 weeks during-COVID-19 (Time 2) and 2 weeks after COVID-19 (Time 3)] and compared with those without infection. Results A significant reduction of TIR (Time 1 vs Time 2, %, 60.1 ± 16.6 vs 55.4 ± 19.2, P = 0.03), associated with a significant increase of TAR level 2 (10.1 ± 7.3 vs 16.7 ± 12.9, P < 0.001), GMI (7.1 ± 0.6 vs 7.5 ± 0.8, P < 0.001), CV (37.3 ± 7.1 vs 39.6 ± 7.0, P = 0.04), mean glucose values (mg/dL, 160.2 ± 26.5 vs 175.5 ± 32.6, P = 0.001) and standard deviation (59.2 ± 13.1 vs 68.6 ± 17.7, P = 0.001) was observed in patients with COVID-19. No significant change of glycemic metrics was found in the NO COVID-19 group across the time. Conclusion Young home-isolated patients with type 1 diabetes and COVID-19 showed a worsening of glucose control during COVID-19, as compared with age-matched diabetic subjects without the infection.

show abstract

Prevalence of SARS-CoV-2 Antibodies in Children and Adults with Type 1 Diabetes

Cited by 29 publications

References 26 publications

Anti-SARS-CoV-2 antibodies in new-onset type 1 diabetes in children during pandemic in Belgium

Anti-SARS-CoV-2 antibodies in new-onset type 1 diabetes in children during pandemic in Belgium

Impaired Glucose-Insulin Metabolism in Multisystem Inflammatory Syndrome Related to SARS-CoV-2 in Children

Glucose control in home-isolated adults with type 1 diabetes affected by COVID-19 using continuous glucose monitoring

Contact Info

Product

Resources

About